Rhön-Klinikum starts PRO-HYPO randomized trial comparing hypofractionated proton vs IMRT radiation in prostate cancer

Bitget2026/10/14 10:58

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Rhön-Klinikum announced recruitment has started for the randomized PRO-HYPO prostate cancer radiotherapy study at its Marburg ion-beam center.
No results have been presented yet; the trial will track side effects, quality of life, and longer-term outcomes over five years.
The study aims to determine whether hypofractionated proton therapy reduces bowel and bladder complications versus hypofractionated IMRT photon therapy.
Enrollment targets 202 men with non-metastatic disease receiving radiation as primary treatment, supporting positioning for proton therapy capacity utilization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhön-Klinikum AG published the original content used to generate this news brief on October 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Rhön-Klinikum starts PRO-HYPO randomized trial comparing hypofractionated proton vs IMRT radiation in prostate cancer

You may also like

Crypto prices